SureTrader
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

MCET RSS Feed
Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66
Search This Board:
Last Post: 8/31/2016 2:23:37 PM - Followers: 534 - Board type: Free - Posts Today: 5

 
MultiCell Technologies, Inc. (MCET)

(U.S. Reporting: SEC Filer) 

Outstanding shares 5,000,948,700 as of Jul 8, 2015 

Office: (401) 762-0045  |  Email: info@multicelltech.com

http://www.MultiCellTech.com

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)


Partners

AmarinCorningPhizer

 

MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS) to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

Under the terms of the agreement, Oxis will pay MultiCell a license fee of $500K, up to $12.75M in clinical development milestones and a royalty of 3% on net sales. Oxis will also reimburse MultiCell up to $1.125M in development costs. MultiCell grants Oxis an option to purchase manufacturing rights to the three ADCs upon the payment of an additional $10M.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:

MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

 Therapeutic Candidate  

   Indication    

    Discovery Optimization    

    Preclinical Development    

    Phase 1    

    Phase 2/b   

    Phase 3    

 MCT-125 

PMSF

yes yes yes yes  

MCT-465

Cancer

yes yes      

MCT-475

Cancer

yes yes      

MCT-485

Cancer

yes yes      


Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.


MultiCell Technologies, Inc. Corporate Headquarters


68 Cumberland Street, Suite 301
Woonsocket, RI 02895


MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.


Find us on Google Maps      http://www.facebook.com/MCET.OB  
 


 Management and Board of Directors


Barbara (Corbett) Newmin - Investor Relations
Office: 941-637-9883



W. Gerald Newmin, Chairman and Chief Executive Officer
Office: 
817-292-7324


Dr. Steve Chang Ph. D., Director




Grant Miller, Director


Alan Tuchman, M.D.

Thomas A. Page, Director

Edward Sigmond, Director



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCET
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#41560   This is going to run and with 50 The dead cat bouncer 08/31/16 02:23:37 PM
#41559   Oh here is the link The dead cat bouncer 08/31/16 01:22:48 PM
#41558   They have been quietly working and they are The dead cat bouncer 08/31/16 01:19:40 PM
#41557   Nah, MCET shareholders are/were the dreamers. ?? simon wagstaff 08/31/16 10:53:41 AM
#41556   Gerald and Barb the dreamers.. Dip66 08/31/16 10:15:24 AM
#41555   New standard helps ensure accurate clinical measurements of TPX 08/30/16 10:48:51 AM
#41554   Molecular switch may sensitize triple-negative breast cancers to immunotherap TPX 08/30/16 10:42:42 AM
#41552   That is not MCET news. MCT 125 is simon wagstaff 08/25/16 07:24:51 AM
#41551   MCET NEWS! Fatigue Market Pipeline 2016 Global Therapeutics TPX 08/25/16 06:09:40 AM
#41550   I don't think there was really all that simon wagstaff 08/23/16 03:56:06 PM
#41549   It's to bad MultiSmell missed the boat on Dip66 08/23/16 11:36:06 AM
#41548   The Big Idea: Treating cancer with immunotherapy TPX 08/23/16 07:13:09 AM
#41547   TPX - I don't disagree with the links Dip66 08/20/16 01:09:59 AM
#41546   Dr. Hurvitz on Steps to Take With HER2-Positive TPX 08/19/16 10:19:49 AM
#41545   New NIST Standard Reference Material helps ensure accurate TPX 08/19/16 10:18:16 AM
#41543   On this volume? 10 bucks at a simon wagstaff 08/19/16 07:15:30 AM
#41542   Customizing a Cure: The Pioneering Science Behind Cancer Immunotherapy TPX 08/19/16 06:52:40 AM
#41541   Gerald is prob trying to squeeze every last Dip66 08/19/16 12:00:57 AM
#41540   A few are making some $ here. Tick Rocco5 08/18/16 10:21:48 PM
#41539   i seen that also tpx exposed. Dip66 08/18/16 09:23:20 PM
#41538   2002-2015 presenters, simon wagstaff 08/18/16 04:18:39 PM
#41537   Of what? Please be specific. simon wagstaff 08/18/16 04:17:03 PM
#41536   Multicell Technologies, Inc. Annual Global Investment Conference SEPTEMBER TPX 08/18/16 01:16:04 PM
#41535   Merger? Buy-out? Acquisition? Termite7 08/18/16 01:13:43 PM
#41534   Great Hope for Immunotherapy TPX 08/18/16 11:16:45 AM
#41533   I don't think there is any pretending, and simon wagstaff 08/18/16 10:05:08 AM
#41532   Stop posting this nonsense pretending something is happening Dip66 08/18/16 09:46:18 AM
#41531   New standard helps ensure accurate clinical measurements of TPX 08/18/16 04:34:09 AM
#41530   T-Cell Immunotherapy for Cancer - Pipeline Analysis TPX 08/17/16 09:50:19 AM
#41529   Neither, reverse split must be approved by shareholders. simon wagstaff 08/16/16 02:42:42 PM
#41528   Run or Reverse Split? Termite7 08/16/16 02:08:28 PM
#41527   USPTO Offers a Fast Track to Cancer Immunotherapy TPX 08/16/16 01:55:26 PM
#41526   Immunotherapy: a New Weapon Against Cancer TPX 08/16/16 01:52:38 PM
#41525   I'm just waiting for Hay Day when they The dead cat bouncer 08/16/16 12:58:14 PM
#41524   OK, you guys think you are so clever, simon wagstaff 08/15/16 07:41:06 PM
#41523   Breakthrough cancer treatment focuses on immunotherapy TPX 08/15/16 07:29:35 PM
#41522   A promising new set of cancer drugs has TPX 08/15/16 07:16:59 PM
#41521   How did you trap him so easily? The dead cat bouncer 08/15/16 06:46:22 PM
#41520   Curious . . . I never mentioned shorting either. mrroundtree 08/15/16 04:17:29 PM
#41519   I wish I could be shorting MCET, really simon wagstaff 08/15/16 04:12:07 PM
#41518   Just sayin' . . . after two thousand mrroundtree 08/15/16 03:47:58 PM
#41517   My wisdom is for you, totally without compensation. simon wagstaff 08/15/16 03:40:52 PM
#41516   Funny you should bring that up. mrroundtree 08/15/16 01:22:24 PM
#41515   Must be getting paid by the post. simon wagstaff 08/15/16 07:02:59 AM
#41514   Manhattan cancer survivor Mary Elizabeth Williams helped pave TPX 08/15/16 03:59:33 AM
#41513   Barbara is making paintings and selling them to Dip66 08/14/16 10:22:35 AM
#41512   Sorry, the MS thing is long gone. Two simon wagstaff 08/13/16 12:11:46 PM
#41511   we know, Brother bontooth 08/13/16 04:09:31 AM
#41510   What's disgusting is how Barbara blocks investors on Dip66 08/12/16 12:02:29 PM
#41509   There is no product, office, or working phone Dip66 08/12/16 11:41:35 AM
PostSubject